Serum Galectin-3 Levels Predict Poor Prognosis in Sepsis and Septic Shock Patients

Overview

Journal Rev Assoc Med Bras (1992)

Specialty General Medicine

Date 2023 Aug 23

PMID 37610926

Authors

Pinar Karabacak

Affiliations

Soon will be listed here.

Abstract

Objective: Sepsis and septic shock are clinical conditions with high mortality and an ever-increasing prevalence, and early diagnosis is of great importance in treating these diseases. Increase in serum Galectin-3 protein in septic patients is associated with increased inflammation, which in turn is associated with mortality. This study aimed to investigate the diagnostic importance of serum Galectin-3 levels and its relationship with in-hospital mortality in sepsis and septic shock patients.

Methods: This prospective cohort study included 44 sepsis and 44 septic shock patients. Sequential Organ Failure Assessment score and Acute Physiology and Chronic Health Evaluation 2 score were calculated. In addition, routine clinical and laboratory parameters along with serum Galectin-3 were evaluated.

Results: Serum Galectin-3 levels were significantly higher in the septic shock group [4.1 (0.1-10.2) vs. 6.0 (0.1-11.3) ng/mL, respectively; p=0.01]. Moreover, patients with a Galectin-3 level <6.94 ng/mL were associated with longer survival [31.4 vs. 23.1 days; hazards ratio, 1.85; 1.03-3.34, p=0.03]. More importantly, the need for mechanical ventilation, the duration of mechanical ventilation, and serum Galectin-3 levels were independent prognostic factors and predicted poor in-hospital survival in both sepsis and septic shock patients.

Conclusion: These findings suggest that Galectin-3 levels are higher in septic shock patients and predict mortality. In addition, high serum Galectin-3 levels, together with mechanical ventilation requirement and mechanical ventilation duration, are closely associated with poor in-hospital survival. Therefore, Galectin-3 may be a valuable diagnostic and prognostic biomarker in these patients.

References

Singer M, Deutschman C, Seymour C, Shankar-Hari M, Annane D, Bauer M . The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016; 315(8):801-10. PMC: 4968574. DOI: 10.1001/jama.2016.0287. View

Quattroni P, Li Y, Lucchesi D, Lucas S, Hood D, Herrmann M . Galectin-3 binds Neisseria meningitidis and increases interaction with phagocytic cells. Cell Microbiol. 2012; 14(11):1657-75. PMC: 3749814. DOI: 10.1111/j.1462-5822.2012.01838.x. View

Faix J . Biomarkers of sepsis. Crit Rev Clin Lab Sci. 2013; 50(1):23-36. PMC: 3613962. DOI: 10.3109/10408363.2013.764490. View

Almeida F, Wolf J, da Silva T, DeLeon-Rodriguez C, Rezende C, Pessoni A . Galectin-3 impacts Cryptococcus neoformans infection through direct antifungal effects. Nat Commun. 2017; 8(1):1968. PMC: 5719036. DOI: 10.1038/s41467-017-02126-7. View

Pereira-da-Silva T . Galectin-3: A simple tool for a complex clinical issue?. Rev Port Cardiol (Engl Ed). 2021; 40(11):837-838. DOI: 10.1016/j.repce.2021.10.020. View

Kim H, Hur M, Moon H, Yun Y, Di Somma S . Multi-marker approach using procalcitonin, presepsin, galectin-3, and soluble suppression of tumorigenicity 2 for the prediction of mortality in sepsis. Ann Intensive Care. 2017; 7(1):27. PMC: 5340789. DOI: 10.1186/s13613-017-0252-y. View

Sato S, Ouellet N, Pelletier I, Simard M, Rancourt A, Bergeron M . Role of galectin-3 as an adhesion molecule for neutrophil extravasation during streptococcal pneumonia. J Immunol. 2002; 168(4):1813-22. DOI: 10.4049/jimmunol.168.4.1813. View

Li Y, Komai-Koma M, Gilchrist D, Hsu D, Liu F, Springall T . Galectin-3 is a negative regulator of lipopolysaccharide-mediated inflammation. J Immunol. 2008; 181(4):2781-9. DOI: 10.4049/jimmunol.181.4.2781. View

Ten Oever J, Giamarellos-Bourboulis E, van de Veerdonk F, Stelma F, Simon A, Janssen M . Circulating galectin-3 in infections and non-infectious inflammatory diseases. Eur J Clin Microbiol Infect Dis. 2013; 32(12):1605-10. DOI: 10.1007/s10096-013-1919-4. View

10.

Vucelic V, Klobucar I, duras-Cuculic B, Gveric Grginic A, Prohaska-Potocnik C, Jajic I . Sepsis and septic shock - an observational study of the incidence, management, and mortality predictors in a medical intensive care unit. Croat Med J. 2020; 61(5):429-439. PMC: 7684537. View

11.

Fernandez-Martin J, Espinosa-Oliva A, Garcia-Dominguez I, Rosado-Sanchez I, Pacheco Y, Moyano R . Gal3 Plays a Deleterious Role in a Mouse Model of Endotoxemia. Int J Mol Sci. 2022; 23(3). PMC: 8835800. DOI: 10.3390/ijms23031170. View

12.

Mishra B, Li Q, Steichen A, Binstock B, Metzger D, Teale J . Galectin-3 functions as an alarmin: pathogenic role for sepsis development in murine respiratory tularemia. PLoS One. 2013; 8(3):e59616. PMC: 3603908. DOI: 10.1371/journal.pone.0059616. View

13.

Hara A, Niwa M, Noguchi K, Kanayama T, Niwa A, Matsuo M . Galectin-3 as a Next-Generation Biomarker for Detecting Early Stage of Various Diseases. Biomolecules. 2020; 10(3). PMC: 7175224. DOI: 10.3390/biom10030389. View

14.

Wacker C, Prkno A, Brunkhorst F, Schlattmann P . Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis. Lancet Infect Dis. 2013; 13(5):426-35. DOI: 10.1016/S1473-3099(12)70323-7. View

15.

Esposito S, De Simone G, Boccia G, De Caro F, Pagliano P . Sepsis and septic shock: New definitions, new diagnostic and therapeutic approaches. J Glob Antimicrob Resist. 2017; 10:204-212. DOI: 10.1016/j.jgar.2017.06.013. View

16.

Leone M, Mokart D . Editorial: Septic shock: what we should know… or almost!. Curr Opin Anaesthesiol. 2021; 34(2):69-70. DOI: 10.1097/ACO.0000000000000964. View

17.

Song L, Tang J, Owusu L, Sun M, Wu J, Zhang J . Galectin-3 in cancer. Clin Chim Acta. 2014; 431:185-91. DOI: 10.1016/j.cca.2014.01.019. View

18.

Dong R, Zhang M, Hu Q, Zheng S, Soh A, Zheng Y . Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review). Int J Mol Med. 2017; 41(2):599-614. PMC: 5752178. DOI: 10.3892/ijmm.2017.3311. View

19.

Ferreira R, Rodrigues L, Nascimento D, Kanashiro A, Melo P, Borges V . Galectin-3 aggravates experimental polymicrobial sepsis by impairing neutrophil recruitment to the infectious focus. J Infect. 2018; 77(5):391-397. DOI: 10.1016/j.jinf.2018.06.010. View

20.

Dumic J, Dabelic S, Flogel M . Galectin-3: an open-ended story. Biochim Biophys Acta. 2006; 1760(4):616-35. DOI: 10.1016/j.bbagen.2005.12.020. View